Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.
Albarakati N, Abdel-Fatah TM, Doherty R, Russell R, Agarwal D, Moseley P, Perry C, Arora A, Alsubhi N, Seedhouse C, Rakha EA, Green A, Ball G, Chan S, Caldas C, Ellis IO, Madhusudan S.
Albarakati N, et al. Among authors: seedhouse c.
Mol Oncol. 2015 Jan;9(1):204-17. doi: 10.1016/j.molonc.2014.08.001. Epub 2014 Aug 27.
Mol Oncol. 2015.
PMID: 25205036
Free PMC article.
Clinical Trial.